Cochlear , the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Bailey from Morgan Stanley maintained a Sell rating on the stock and has a A$280.00 price target.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
David Bailey has given his Sell rating due to a combination of factors impacting Cochlear’s financial outlook. One of the primary reasons is the company’s guidance for FY26 net profit after tax (NPAT), which suggests a significant reliance on the second half of the fiscal year for growth. This reliance is based on the anticipated launch of the Nexa implant, which introduces uncertainty regarding the timing and success of its market uptake.
Additionally, Morgan Stanley’s forecasts indicate a slight underperformance in NPAT compared to Visible Alpha’s expectations for the first half of FY26. This potential shortfall raises concerns about Cochlear’s ability to meet its full-year guidance, particularly if the Nexa implant does not perform as expected. These factors contribute to a cautious outlook, prompting the Sell rating on Cochlear’s stock.
According to TipRanks, Bailey is a 4-star analyst with an average return of 13.9% and a 46.97% success rate. Bailey covers the Healthcare sector, focusing on stocks such as Cochlear , Telix Pharmaceuticals, and Ansell.